About equillium - EQ
Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly in March, 2017 and is headquartered in La Jolla, CA.
EQ At a Glance
Equillium, Inc.
2223 Avenida de la Playa
La Jolla, California 92037
| Phone | 1-858-240-1200 | Revenue | 36.08M | |
| Industry | Biotechnology | Net Income | -13,335,000.00 | |
| Sector | Health Technology | 2023 Sales Growth | 128.974% | |
| Fiscal Year-end | 12 / 2024 | Employees | 44 | |
| View SEC Filings |
EQ Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.696 |
| Price to Book Ratio | 1.129 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 1.037 |
| Enterprise Value to Sales | -0.414 |
| Total Debt to Enterprise Value | -0.055 |
EQ Efficiency
| Revenue/Employee | 820,090.909 |
| Income Per Employee | -303,068.182 |
| Receivables Turnover | 5.74 |
| Total Asset Turnover | 0.56 |
EQ Liquidity
| Current Ratio | 1.79 |
| Quick Ratio | 1.79 |
| Cash Ratio | 1.482 |
EQ Profitability
| Gross Margin | 99.651 |
| Operating Margin | -40.245 |
| Pretax Margin | -35.348 |
| Net Margin | -36.955 |
| Return on Assets | -20.682 |
| Return on Equity | -48.922 |
| Return on Total Capital | -56.994 |
| Return on Invested Capital | -45.233 |
EQ Capital Structure
| Total Debt to Total Equity | 3.65 |
| Total Debt to Total Capital | 3.522 |
| Total Debt to Total Assets | 1.631 |
| Long-Term Debt to Equity | 1.701 |
| Long-Term Debt to Total Capital | 1.641 |